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Abstract
Objectives—To introduce the combined South African cohorts of the International epidemiologic
Databases to Evaluate AIDS Southern Africa (IeDEA-SA) collaboration as reflecting the South
African national antiretroviral treatment (ART) programme; to characterise patients accessing these
services; and to describe changes in services and patients from 2003 to 2007.
Design and setting—Multi-cohort study of 11 ART programmes in Gauteng, Western Cape, Free
State and KwaZulu-Natal.
Subjects—Adults and children (<16 years old) who initiated ART with ≥3 antiretroviral drugs
before 2008.
Results—Most sites were offering free treatment to adults and children in the public sector, ranging
from 264 to 17 835 patients per site. Among 45 383 adults and 6 198 children combined, median age
(interquartile range) was 35.0 years (29.8 – 41.4) and 42.5 months (14.7 – 82.5), respectively. Of
adults, 68% were female. The median CD4 cell count was 102 cells/µl (44 – 164) and was lower
among males than females (86, 34 – 150 v. 110, 50 – 169, p<0.001). Median CD4% among children
was 12% (7 – 17.7). Between 2003 and 2007, enrolment increased 11-fold in adults and 3-fold in
children. Median CD4 count at enrolment increased for all adults (67 – 111 cells/µl, p<0.001) and
for those in stage IV (39 – 89 cells/µl, p<0.001). Among children <5 years, baseline CD4% increased
over time (11.5 – 16.0%, p<0.001).
Conclusions—IeDEA-SA provides a unique opportunity to report on the national ART
programme. The study describes dramatically increased enrolment over time. Late diagnosis and
ART initiation, especially of men and children, need attention. Investment in sentinel sites will ensure
good individual-level data while freeing most sites to continue with simplified reporting.
The World Health Organization (WHO) estimated that in 2007, 9.7 million people in low- and
middle-income countries needed antiretroviral treatment (ART),1 9% of whom were living in
South Africa.2 By the end of 2007, the South African National Department of Health (DoH)
reported that 371 731 people had initiated highly active antiretroviral therapy (HAART),2
making it the largest ART programme in the world.1 As the public health system has only
provided ART since 2004, this has involved a massive scale-up of services within a
comparatively short space of time.
In the context of such an ambitious undertaking, trends in enrolment and key outcomes must
be understood in order to plan for the changing needs of health services and patients.1
Monitoring is a major challenge to effective delivery of ART at a national level,2 and it becomes
increasingly important as the continued scale-up of ART creates a tension between service
provision and collecting good data.
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tThe International epidemiologic Databases to Evaluate AIDS (IeDEA) Southern Africa
collaboration (IeDEA-SA) has assembled a collaborative individualised dataset of children and
adults starting ART at sites in South Africa. Numerically the collaboration represents 20% of
all children and 10% of all adults entering the public sector roll-out programme. This provides
a unique opportunity to report in detail, based on individual patient data, on a subset of the
national ART programme.
This paper aims to introduce the South African cohorts participating in IeDEA as a
collaboration that reflects the South African national ART programme, to characterise the
children and adults accessing these services, and to describe changes in services and patients
over the past 5 years.
Background and setting
The IeDEA collaboration
IeDEA is an international collaboration of seven regional data centres funded by the National
Institutes of Health (NIH). It was established to pool data across numerous cohorts of patients
on ART, creating large datasets to address research questions that cannot be answered within
single cohorts.
IeDEA Southern Africa
IeDEA-SA is the regional cohort collaboration of southern Africa. Since its establishment in
2006, 22 sites have joined the collaboration. The current database includes cohorts from South
Africa, Zimbabwe, Mozambique, Zambia, Malawi and Botswana. Some countries have more
than one cohort participating, providing an opportunity to describe characteristics and
outcomes at a national level, in the absence of good routine national monitoring systems. In
South Africa, 11 large sites from 4 provinces have joined the collaboration.
The South African ART programme
Since the start of the national ART roll-out programme in 2004, the South African guidelines
for initiation of ART3 have recommended treatment for adults with CD4 cell counts <200
cells/µl or WHO stage IV illness except for extrapulmonary tuberculosis, who are assessed to
be willing and ready to take and adhere to ART. Before this, most sites offering ART followed
similar criteria, based on the 2002 WHO guidelines.4 First-line therapy in ART-naïve adults,
unless contraindicated, is stavudine (d4T), lamivudine (3TC) and efavirenz (EFV) or
nevirapine (NVP). Women of child-bearing age who are unable to guarantee reliable
contraception should receive NVP instead of EFV. Patients receive monthly medication and
are seen by a doctor at 4, 8 and 12 weeks and 3-monthly thereafter if well. CD4 count and viral
load are measured 6-monthly. Patients with a detectable viral load (>400 copies/µl) receive a
stepped-up adherence package. If their viral load persistently exceeds 5 000 copies/µl despite
adherence support, they may be switched to second-line therapy. Second-line therapy
comprises zidovudine (AZT), didanosine (ddI) and lopinavir/ritonavir (LPV/r). Drug
substitutions are also made if patients experience toxicity on first-line therapy.
The 2004 South African paediatric guidelines3 recommend ART initiation based on a
confirmed HIV diagnosis (HIV DNA polymerase chain reaction (PCR) testing if the child is
<18 months of age) and one of the following criteria: (i) recurrent hospitalisations (>2
admissions/year) or prolonged hospitalisation (>4 weeks) for HIV-related illness; (ii) WHO
stage III/IV disease; or (iii) CD4 <20% if under 18 months or <15% for older children. Based
on the new WHO staging,5 most paediatric sites changed from the 3- to the 4-stage system
towards the end of 2004, which may have impacted to some extent on the paediatric staging
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tdata in this dataset. Paediatric first-line ART for children from 6 months to 3 years is d4T, 3TC
and LPV/r. For children >3 years and >10 kg, EFV replaces LPV/r.
Methods
Study population
Most participating ‘sites’ comprise single clinics in urban or peri-urban areas. The definition
of site is broad: one site encompasses 3 clinics, and another includes all the facilities within an
entire province, from primary to tertiary level. The study included data on all adults and children
(<16 years old) with documented age, gender and ART start date who initiated ART with at
least 3 antiretrovirals before 2008.
Data collection and management
The study utilised data that are routinely collected by sites. All sites have current ethics
committee approval for contribution of their data to IeDEA analyses. The data were all
anonymised before transfer to the data centre. Sites submitted data during the course of 2007
and early 2008. Data on programme-level characteristics were collected through site
assessment questionnaires.
Data analysis
Cleaning, coding and analysis of data were done in Intercooled STATA 10.0 for Windows
(STATA Corporation, College Station, TX). Continuous variables were described by medians
and interquartile ranges and categorical variables as proportions. Temporal trends were tested
using the Kruskal-Wallis test (continuous variables) and the chi-square test (categorical
variables).
Results
Programme-level characteristics
Seven of the sites offer services to children and adults, either in separate or combined clinics
(Table I); 1 site treats children and pregnant women and the other sites treat children or adults
exclusively. Nine sites are public programmes funded largely by the DoH with strong research
partnerships. One site is funded entirely by donor funding and another is a not-for-profit
hospital that receives a DoH subsidy and external funding for research projects. The study
utilised data on adult patients from 8 sites, contributing between 642 and17 835 patients. Seven
sites contributed data on paediatric patients, contributing between 264 and 2 226 patients.
Treatment was free to all patients except those attending the state-subsidised hospital, who
were charged a small inclusive monthly co-payment. Although most sites reported active
follow-up of patients, follow-up of defaulting patients was generally limited owing to resource
constraints. Patients were referred for treatment primarily from clinics, hospital wards and
other medical facilities. Treatment readiness and patient preparation was fairly consistent
across sites, involving a baseline psychosocial assessment and 3 individual or group education
sessions over 3 consecutive weeks. This process could be fast-tracked if the patient was
pregnant or required immediate treatment for medical reasons. Patients were encouraged to
disclose their HIV status and to have ‘treatment buddies’, and were referred to support groups
where available.
Characteristics of patients
The analysis included 45 383 adults and 6 198 children. The median age among adults was 35
years (interquartile range (IQR) 29.8 – 41.4) and among children 42.5 months (IQR 14.7 –
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t82.5) (Table II). Of children, 21.2% (N=1 315) and 38.9% (N=2 411) were aged <1 year and
≥5 years, respectively. Adult patients were predominantly female (67.6%, N=30 684). In
contrast, the gender balance of children was even.
Among adults, the median CD4 cell count was 102 cells/µl (IQR 44 – 164). The median CD4
count was lower among adult males than females (86 v. 110 cells/µl, p<0.001). Among patients
with baseline CD4 counts, the majority (89.4%, N=30 105) commenced therapy with CD4 cell
counts below 200/µl. A total of 9 363 adult patients (27.8%) initiated ART with CD4 counts
<50 cells/µl.
Among children, the median CD4% was 12.0% (IQR 7.0 – 17.7), and 64.6% of paediatric
patients (N=3 004) initiated therapy with CD4% <15%. In cohorts reporting WHO staging
(28.1% of adults, N=12 763 and 66.5% of children, N=4 120) most patients had advanced HIV
disease (WHO stage III or IV).
In line with the national protocol, the majority of adult patients (87.7%, N=31 852) started on
a regimen containing d4T and 3TC as the two nucleoside reverse transcriptase inhibitors
(NRTIs); 68% (N=24 734) of adults and 53% (N=2 846) of children started on a regimen
containing EFV. Data on previous ART and prevention of mother-to-child (PMTCT) exposure
were limited. Where previous ART exposure was recorded, most adults (93%, N=22 062) and
children (96%, N=4 100) were reportedly ART-naïve. In cohorts that reported PMTCT
exposure, 13% (N=696) of women and 25% of children (N=617) were known to have been
exposed. Reliable data on tuberculosis (TB) at ART initiation were available from 2 adult and
2 paediatric cohorts. Among these adult patients, 3 722 (21%) had TB, while the proportion
among children was slightly higher (32%, N=1 052). Of the 3 adult cohorts that provided
pregnancy data (N=8 828 female patients), 7% of female patients (N=633) were pregnant at
ART initiation. In these cohorts, median CD4 count was higher among pregnant women than
those who were not pregnant (150 v. 104, p<0.001) and higher among non-pregnant women
than men (104 v. 80, p<0.001).
Temporal trends
Table III shows temporal trends in enrolment, absolute and percentage CD4 and WHO stage.
Over 5 years, patient numbers increased nearly 11-fold among adults (from 1 462 to 15 628),
and 3-fold among children (from 376 to 1 139). The majority of adults in this analysis (63%,
N=28 643) started treatment in 2006 – 2007. Although paediatric enrolment appeared to drop
substantially in 2007, this is probably because data from one of the largest paediatric cohorts
were not available for the second half of 2007.
There was an increase in overall adult baseline CD4 count, from a median of 67 cells/µl (IQR
23 – 134) in 2003 to 111 cells/µl (IQR 49 – 171; p<0.001) in 2007, although the rate of increase
declined over the years. Of all the paediatric patients, 3 787 (61%) were <5 years of age. Among
these patients, baseline CD4% was available for 76% (N=2 884) and median CD4% increased
from 11.5% (IQR 7.1 – 18) in 2004 to 16.0% (11.0 – 22.8; p<0.001) in 2007. In cohorts that
provided data on staging, the proportion of adult patients in stage IV at enrolment fell from
50.3% (N=494) in 2003 to 26.9% (N=800) in 2007 (p<0.001). This was mirrored by an increase
in median CD4 count in this group from 39 cells/µl (IQR 13 – 93) in 2003 to 89 cells/µl (IQR
40 – 162; p<0.001) in 2007. Over time, the availability of baseline CD4 cell counts decreased
from 72.2% to 64.8%.
Variation between sites
Table IV and Table V demonstrate some degree of heterogeneity in patient characteristics
between sites. Median adult age at enrolment ranged from 32 to 36 years. Baseline median
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tCD4 cell count ranged from 85 to 121 cells/µl. Within the paediatric sites, patients at two
exclusively tertiary paediatric hospitals were younger, with a greater proportion <1 year, than
those from other sites.
Discussion
IeDEA-SA: the South African collaborative cohort
This paper introduces the South African sites of IeDEA-SA, a dynamic collaboration that offers
an excellent opportunity to provide information on the South African ART programme. It
describes the baseline characteristics and temporal trends of the largest national cohort yet
assembled of adults and children starting ART. The collaborative cohort is representative of
patients accessing ART through the national programme in large urban centres, which
constitute the largest part of this programme. It is constrained by the absence of cohorts from
some provinces and by limited participation from rural sites. Many of the sites linked to
research programmes may also have more capacity for monitoring than other sites in the
national programme. The cohorts included in this collaboration have dramatically increased
enrolment in line with the national roll-out of treatment, and demonstrate the same uniformity
of clinical practice and patient preparation recommended in national guidelines.
Evidence of national scale-up
The massive increase in enrolment over time, especially over the last 2 years, provides strong
evidence of the successful scale-up of ART in South Africa. Patients are enrolling with less
advanced disease in urban sites: among patients with a baseline CD4 count, there has been a
trend towards higher CD4 count at initiation, and the proportion of patients in stage IV has
decreased.
Late diagnosis and initiation of treatment
Patients in this combined cohort were still being diagnosed and started on ART later than
recommended in national and international guidelines, increasing their risk of early mortality
on treatment.6 In our collaborative cohort, more than 25% of patients started with a CD4 count
<50 cells/µl, and similarly with stage IV disease. Earlier diagnosis and initiation of ART would
reduce the risk of morbidity and mortality among these patients, especially for men, who
present with more advanced HIV disease and appear to be disadvantaged in their access to
treatment.7,8
Children
The paediatric component of this collaboration is to our knowledge the largest national cohort
of children on ART in the world. While the successful enrolment of so many children on ART
is encouraging, limited success in preventing vertical transmission of HIV remains a major
concern.
In addition, children also started ART later than is now internationally recommended.9 South
African data have demonstrated the high risk of disease progression and mortality in the first
year of life.10,11 The low proportion enrolled in the first year of life in this cohort, and high
numbers of children with advanced disease, suggest massive under-diagnosis and missed
treatment opportunities, and an enormous hidden burden of morbidity and mortality among
children.
First-line regimen
Unlike many countries in southern Africa, in which the first-line regimen is a fixed-dose
combination of d4T, 3TC and NVP, EFV use predominates in adults on treatment in South
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tAfrica in spite of the higher cost of EFV-based regimens. Analyses in South Africa have,
however, reported inferior virological outcomes in patients on NVP-containing compared with
EFV-containing regimens.12,13 For many adults starting ART, concomitant TB at the time of
starting ART precludes the use of NVP. In addition, the greater toxicity profile of NVP
compared with EFV has discouraged many clinicians from using it as first-line treatment. The
use of protease inhibitors (PIs) versus non-nucleoside reverse transcriptase inhibitors
(NNRTIs) in children in this analysis is in line with the proportions of children starting ART
above and below 3 years of age.
Data challenges and the need for sentinel surveillance
Although South Africa has implemented the largest treatment programme in the world, the
ability to monitor the programme closely has not kept pace with this expansion.2 The lack of
complete data on baseline characteristics in these cohorts – among the best-monitored ART
programmes nationally – provides insight into the pressures facing the public health system.
Numerous challenges face cohort analysis of ART programmes in developing countries,
chiefly the need to balance service provision and the collection of good-quality data in the face
of rapidly increasing patient numbers. An 11-fold increase in patients over 5 years is bound to
result in a corresponding decrease in data quality unless substantial resources are provided to
support monitoring systems. For health care workers, providing access to clinical care is – and
should be – the priority. It is therefore essential to find ways to avoid overwhelming health
care providers and prioritising monitoring over service provision.14 Establishing selected,
representative sentinel surveillance sites may facilitate the collection of good-quality
individual data on a subset of patients in the national programme, thus freeing most government
sites to continue with simplified aggregate reporting.15
Conclusion
The South African cohorts participating in IeDEA-SA provide a unique opportunity to
undertake analyses of the national ART programme based on individual patient data, to
complement routine monitoring. This analysis demonstrates the massive scale-up in recent
years and the improvement in the level of disease severity at ART initiation. Earlier diagnosis
and enrolment of patients, particularly children and men, need to be prioritised. A solid
investment in representative sentinel surveillance could support a context-appropriate national
ART monitoring system.
IeDEA Southern Africa Steering Group
Member sites—Diana Dickinson, Gaborone Independent Hospital, Gaborone, Botswana;
Brian Eley, Red Cross Children’s Hospital, Cape Town, South Africa; Lara Fairall, Free State
provincial ARV roll-out, South Africa; Tendani Gaolathe, Princess Marina Hospital,
Gaborone, Botswana; Janet Giddy, McCord Hospital, University of KwaZulu-Natal, Durban,
South Africa; Timothy Meade, CorpMed Clinic, Lusaka, Zambia; Patrick MacPhail, Themba
Lethu Clinic, Helen Joseph Hospital, Johannesburg, South Africa; Lerato Mohapi, Perinatal
HIV Research Unit, Johannesburg, South Africa; Margaret Pascoe, Newlands Clinic, Harare,
Zimbabwe; Hans Prozesky, Tygerberg Academic Hospital, Stellenbosch, South Africa; Harry
Moultrie, University of Witwatersrand Paediatric HIV Clinics (Harriet Shezi Clinic, Chris Hani
Baragwanath Hospital) Johannesburg, South Africa; Karl Technau, University of
Witwatersrand Paediatric HIV Clinics (Empilweni Clinic, Rahima Moosa Mother & Child
Hospital), Johannesburg, South Africa; Gilles van Cutsem, Khayelitsha ART Programme and
Médecins sans Frontières, Cape Town, South Africa; Paula Vaz, Paediatric Day Hospital,
Maputo, Mozambique; Anna Coutsoudis, Cato Manor, Durban, South Africa; Ralf Weigel,
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Table I
Characteristics of IeDEA-SA sites providing paediatric and adult ART in South Africa
Cohort Level of
care
No. of
patients in
dataset
Type of site Patients 1st year
ART
provision
Cost
to patient
Tracing
of
patients
LTFU
Main sources of
referral
to site
Empilweni
Clinic,
Johannesburg
All levels 1 088
children
Public &
research
Children
&
pregnant
women
2002 Free No Hospital wards
Free State
provincial roll-out
programme
All levels 17 835 adults Public Adults &
children,
mostly in
combined
clinics
2003 Free Active
tracing*
in
smaller
facilities
Clinics: primary health
care, TB, antenatal
Gugulethu,
Cape Town
Primary 2 924 adults
264 children
Public &
research
Adults &
children,
separate
clinics
2002 Free Active
tracing
Other medical
facilities;
clinics: PMTCT, TB
Harriet Shezi
clinic,
Johannesburg
All levels 2 226
children
Public &
research
Children
only
2002 Free Active
tracing
Hospital wards
Khayelitsha,
Cape Town
Primary 8 119 adults
662 children
Public &
research
Adults &
children,
combined
clinic
2001 Free Phone
call only
Clinics: PMTCT, TB;
other medical facilities
Masiphumelele,
Cape Town
Primary 642 adults Public &
research
Adults &
children
2003 Free Active
tracing
Clinics: PMTCT, STIs,
TB; other medical
facilities
McCord
Hospital,
Durban
Secondary 3 575 adults
415 children
Government-
subsidised,
not-for-profit
hospital
Adults &
children,
combined
clinic
1999
(drug
trial);
2000 (fee-paying);
2004
onwards
(PEPFAR
funding)
Small co-
payment
Active
tracing
Clinics: PMTCT, TB;
other medical facilities
Perinatal HIV
Research Unit,
Johannesburg
Tertiary 948 adults Research Adults &
children,
combined
clinics
2004 with
some
trials
<2004
Free Active
tracing
Wellness programme
for
people with HIV in unit
Red Cross
Children’s
Hospital, Cape
Town
Tertiary 859 children Public &
research
Children
only
2001 Free Active
tracing
Hospital wards
Themba Lethu,
Johannesburg
Tertiary 9 250 adults Public &
research
Adults 2004 Free Active
tracing
Other medical facilities
Tygerberg
Hospital, Cape
Town
Tertiary 1 504 adults
684 children
Public &
research
Adults &
children,
separate
clinics
2004, with
some
trials
<2004
Free Active
tracing
Other medical
facilities;
clinics: PMTCT, TB
*
Active tracing implies dedicated resources to undertake one or more of the following: telephone call, home follow-up, physician’s report and/or data
linkage.
LTFU = lost to follow-up; PMTCT = prevention of mother-to-child-transmission programme; TB = tuberculosis; STIs: sexually transmitted infections.
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Table II
IeDEA South African cohort, patient characteristics at ART initiation: 45 383 adults and 6 198 children followed
up in 11 IeDEA-SA sites in South Africa, 2003 – 2007
Characteristic Adults (≥16 yrs)
N=45 383
Children
N=6 198
Age N=45 383 (100%) N=6 198 (100%)
 Adults (yrs), median (IQR) 35.0 (29.8 – 41.4)
 Children (mo.), median (IQR) 42.5 (14.7 – 82.5)
 Age categories, N(%)
  <12 mo. 1 315 (21.2)
  12 – 23 mo. 891 (14.4)
  24 – 59 mo. 1 581 (25.5)
  ≥60 mo. 2 411 (38.9)
Gender N=45 383 (100%) N=6 198 (100%)
 Female, N (%) 30 684 (67.6) 3 051 (49.2)
Absolute CD4 cell count (cells/µl) N=33 672 (75.2%)* N=4 900 (79.1%)
 All adults, median (IQR) 102 (44 – 164)
  Men 86 (34 – 150)
  Women 110 (50 – 169)
 CD4 cell count categories, N(%)
  <50 9 363 (27.8)
  50 – 199 20 742 (61.6)
  ≥200 3 567 (10.6)
All children, median (IQR) 391 (172 – 730)
CD4% N/A N=4 648 (75.0)†
 Median (IQR) 12.0 (7.0 – 17.7)
 CD4% categories, N (%)
  <15% 3 004 (64.6)
  15 – 19% 760 (16.4)
  ≥20% 884 (19.0)
WHO stage, N (%) N=12 763 (28.1)‡ N=4 120 (66.5)§
 I 1 134 (8.9) 270 (6.5)
 II 1 512 (11.9) 752 (18.3)
 III 6 118 (47.9)
 IV 3 999 (31.3) 3 098 (75.2)¶
HIV RNA level (log10 copies/ml) N=14 955 (33.0)□ N=4 116 (66.4)
 Median (IQR) 4.89 (4.34 – 5.41) 5.3 (4.7 – 5.9)
1st-line ART regimen used, N(%) N=36 319 (81.1)** N=5 331 (86.0)
 d4T+3TC+EFV 23 568 (64.9) 2 692 (50.5)
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Characteristic Adults (≥16 yrs)
N=45 383
Children
N=6 198
 d4T+3TC+NVP 8 284 (22.8) 93 (1.7)
 AZT+3TC+NVP 1 350 (3.7) 74 (1.4)
 AZT+3TC+EFV 1 166 (3.2) 154 (2.9)
 d4T+3TC+KLT†† 1 343 (25.2)
 d4T+3TC+RTV 268 (5.0)
 Other 1 951 (5.4) 707 (13.3)
Previous ART exposure, N(%) N=23 735 (53.0)‡‡ N=4 262 (68.8)
 ART exposure 1 673 (7.1) 162 (3.8)
PMTCT exposure, N (%) N=5 526 (12.3)§§ N=2 430 (39.2)¶¶
 Known exposed women/children 696 (12.6) 617 (25.4)
TB at ART initiation, N(%) N=17 369 (38.8)□□ N=3 305 (53.3)
 Yes 3 722 (21.4) 1 052 (31.8)
Pregnant at ART initiation, N(%) N=8 828*** N/A†††
 Yes 633 (7.2)
*
Data from all cohorts; CD4 not always provided in dataset.
†
Data from 6 paediatric cohorts.
‡
Includes data from 4 cohorts.
§
Data from all cohorts; WHO stage not always provided in dataset.
¶
Stages III & IV combined for children.
□
Data from all cohorts; viral load not always provided in dataset.
**
Only listed those regimens prescribed to >4% of adult patients.
††
Includes 209 children on ritonavir and Kaletra.
‡‡
Data from 3 cohorts.
§§
Data from 2 cohorts.
¶¶
Data from 4 cohorts.
□□
Data from 2 cohorts.
***
Data on female patients from 3 cohorts.
†††
Data not provided in paediatric datasets.
IQR = interquartile range; TB = tuberculosis.
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Table III
IeDEA South African cohort: temporal changes
Year of ART initiation ≤2003 2004 2005 2006 2007
p
-value
for
trend Combined
Patients enrolled, N (%)
 Adults 1 462 (3.2) 5 340 (11.8) 9 938 (21.9) 13 015 (28.7) 15 628 (34.4) 45 383 (100)
 Children 376 (6.0) 1 094 (17.7) 1 849 (29.8) 1 740 (28.1) 1 139 (18.4) 6 198 (100)
Baseline CD4 (cells/µl)
 All adults N 1 055 4 597 8 476 9 417 10 127 33 672
Med. (IQR) 67 (23 –
134)
86 (38 –
147)
101 (43 –
159)
105 (45 –
168)
111 (49 –
171)
<0.001 102 (44 –
164)
 Men N 341 1 433 2 726 3 177 3 397 11 074
Med. (IQR) 54 (18 –
123)
74 (33 –
138)
87 (33 –
149)
88 (34 – 154) 93 (36 – 154) <0.001 86 (34 – 150)
 Women N 714 3 164 5 750 6 240 6 730 22 598
Med. (IQR) 74 (26 –
138)
91 (41 –
150)
107 (48 –
164)
115 (52 –
174)
120 (56 –
179)
<0.001 110 (50 –
169)
Children <5 yrs N 638* 1 160 1 091 684 3 787
 CD4% Med. (IQR) 11.5 (7.1 –
18)
12.2 (8.1 –
17.6)
14.0 (9.4 –
20)
16.0 (11.0 –
22.8)
<0.001 13.0 (8.7 –
19)
Adults in stage IV N (%) 494 (50.3) 708 (38.5) 998 (31.3) 999 (26.5) 800 (26.9) 3 999 (33.3)
Med. CD4, <0.001
cells/µl (IQR) 39 (13 –
93)
54 (20 –
115)
68 (24 –
138)
74 (29 – 147) 89 (40 – 162) 66 (25 – 236)
Availability of
laboratory tests
at baseline CD4 cell count 72.2% 86.1% 85.3% 72.4% 64.8% 74.2%
CD4% <5 yrs 74.9% 77.2% 78.6% 71.9% 76.2%
*
In this table, all children <5 yrs before 2004 were combined owing to low numbers and erratic enrolment in different research sites.
Med. = median; IQR = interquartile range.
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Table IV
Adult patient characteristics by cohort
Cohort
Free State
province Gugulethu Khayelitsha Masiphumelele McCord PHRU
Themba
Lethu Tygerberg
Adults enrolled,
N
(%) 17 835 (39.3) 2 924 (6.4) 8 119 (17.9) 642 (1.4) 3 575 (7.9) 948 (2.1) 9 836 (21.7) 1 504 (3.3)
Age (yrs), med.
(IQR) 36 (31 – 43) 33 (29 – 39) 33 (28 – 39) 32 (27 – 37) 35 (30 – 41)
34 (30 –
40) 35 (30 – 41)
34 (29 –
41)
CD4 cell count
(cells/µl), med.
(IQR)
114 (55 –
167)
101 (48 –
158)
101 (45 –
165) 121 (46 – 193)
85 (31 –
152)
108 (43 –
171)
88 (32 –
158)
116 (52 –
174)
Patients with
CD4
<50 cells/µl, N
(%) 2 175 (22.1) 631 (25.4) 1 932 (27.3) 152 (25.8) 1 025 (35.1) 197 (25.7) 2 966 (33.7) 284 (23.9)
med. = median; IQR = interquartile range.
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Table V
Paediatric patient characteristics by cohort
Cohort Empilweni Gugulethu Harriet Shezi Khayelitsha McCord Red Cross Tygerberg
Children enrolled,
N (%)
1 088 (17.5) 264 (4.3) 2 226 (35.9) 662 (10.7) 415 (6.7) 859 (13.9) 684 (11.0)
Age (mo.), med.
(IQR) 44 (16 – 85) 47 (19 – 82) 56 (22 – 90) 42 (20 – 74) 72 (33 – 109) 16 (6 – 50) 22 (9 – 57)
Children <1 yr, N
(%) 216 (20) 42 (16) 331 (15) 97 (15) 31 (7) 361 (42) 237 (35)
Children <5 yrs,
CD4%, med. (IQR) 14 (9 – 19) - 12 (7 – 17) 14 (10 – 20) 13 (9 – 17) 14 (9 – 21) 16 (11 – 23)
Children <5 yrs
with CD4 <15%, N
(%) 243 (54) - 707 (66) 145 (52) 30 (58) 367 (56) 168 (44)
med. = median; IQR = interquartile range.
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